Medication Description: Medroxyprogesterone Acetate (Medroxyprogesterone acetate)
MEDROXYPROGESTERONE ACETATE (Medroxyprogesterone acetate). 17-Hydroxy-6 a-methylpregn-4-ene-3; 20-dione acetate.
Synonyms: Depo-Provera, Provera, Farlutal, Clinovir, Depcorlutin, Depo-Alphacort, Depo-Clinovie, Depo-Promone, Depo-Provera, Farlutal, Farmolut, Gestopuran, Luteodione, Metilgestene, Neolut, Nidaxin, Normobion, Ono-o-stione, Metilgestene, Neolut, Nidaxin, Normobion, Ono-o-cione, Luteodione, Metilgestene, Neolut, Nidaxin Prodafem, Promone-E, Provera, Proverone, Sedometril, Vadecin, etc.
The chemical structure is close to the derivatives of progesterone (see) by the main type of action is a progestin (progestogen). As a progestin remedy, it is used for menstrual disorders, dysfunctional uterine bleeding. However, the drug has found its main use as an antitumor agent for hormone-sensitive malignant tumors (see Progesterone capronate), especially for breast cancer and uterine cancer (endometrium). The effect is associated not only with gestagen, but also with antiestrogenic, antiandrogenic and antiagononotropic activity.
In breast cancer, a correlation has been observed between the effectiveness of medroxyprogesterone and the concentration of estrogen and progesterone receptors in the tumor tissue.
The drug can be used as monotherapy or in combination with antiestrogens (see) or cytotoxic drugs.
As an antitumor medroxyprogesterone acetate, it is used mainly for additional or / and palliative therapy for relapses and / or metastases of endometrial cancer and kidney cancer, as well as for the therapy of the recurrence of hormone-dependent breast cancer in postmenopausal women.
The drug is used inside or intramuscularly.
Medroxyprogesterone Provera is available in two forms: a) Provera tablets and b) Depo Provera suspension.
Provera tablets are administered orally for endometrial and kidney cancer from 200 to 600 mg per day, for breast cancer from 400 to 1200 mg per day. The effect is usually noted after 8–10 weeks from the start of treatment.
Depo-provera is administered intramuscularly in the form of a suspension (150 mg of the drug in 1 ml) for endometrial and kidney cancer, 400-1000 mg once a week. With the improvement of the state, the dose is reduced to 400 mg and administered once a month.
In breast cancer, 500 mg is administered daily for 28 days, then 500 mg 2 times a week until the effect persists.
With the progression of the disease, therapy with medroxyprogesterone acetate is stopped (as with the use of other similar drugs).
Possible side effects and contraindications are basically the same as when using other progestin.
When using the suspension seals and sterile abscesses are possible at the injection site.
Method of production: tablets of 100; 200; 250; 400 mg (0.1; 0.2; 0.25; 0.4 g); oral suspension containing 500 mg in 1 ml: suspension for intramuscular injections (depo-provera) in vials of 3, 3 ml (500 mg or 150 mg in 1 ml) and 6, 7 ml (1000 mg).